NCCR Urges Congress to Support Senate Bill for Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--The National Coalition for Cancer Research (NCCR) has activated its 18 member organizations to write to Congress in support of S.1897, the NIH Revitalization Act of 1996. This legislation was introduced in the US Senate by Sen. Nancy Kassebaum (R-KS) to revise and extend certain programs of the NIH, including the National Cancer Institute (NCI).

WASHINGTON--The National Coalition for Cancer Research (NCCR)has activated its 18 member organizations to write to Congressin support of S.1897, the NIH Revitalization Act of 1996. Thislegislation was introduced in the US Senate by Sen. Nancy Kassebaum(R-KS) to revise and extend certain programs of the NIH, includingthe National Cancer Institute (NCI).

The legislation authorizes funding for the NCI at $3 billion andstrikes various cancer-specific earmarks, ie, allocations forbreast cancer, ovarian cancer, and prostate cancer. The NCCR supportsa balanced cancer research agenda and believes that earmarkingof site- and gender-specific research should not be supportedunless additional funds are provided for these priorities.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content